Example collocations logo

Vaccine in sentence

824 examples of Vaccine in a sentence

The same problem will also apply to any potential COVID-19 vaccine.
Unlike Jonas Salk’s polio vaccine, which was made freely available immediately, most vaccines that come to market today are patented.
For example, PCV13, the current multi-strain pneumonia vaccine administered to babies, costs hundreds of dollars because it is the monopoly property of Pfizer.
And although Gavi, the Vaccine Alliance subsidizes some of the costs of the vaccine in developing countries, many people still cannot afford it.
In India, more than 100,000 preventable infant deaths from pneumonia are recorded every year, while the vaccine brings in roughly $5 billion in revenue for Pfizer annually.
As public-health advocates and scholars have long argued, monopolies kill, by denying access to life-saving medicines that otherwise would have been available under an alternative system – like the one facilitating the yearly production of the flu vaccine.
At least until a safe, effective COVID-19 vaccine becomes available, all countries need different forms of tailored, limited lockdowns and rules of behavior.
The federal government has given pharmaceutical companies billions of public dollars to develop a vaccine and, thanks to lobbyists, did not attach conditions on pricing or impose public claims on patents.
World leaders now have an opportunity to seal the deal on a global framework that puts international cooperation above vaccine nationalism in stopping the pandemic.
Given these odds, even wealthy governments that are currently negotiating bilateral deals with individual vaccine manufacturers cannot guarantee access to a vaccine on their own.
By contrast, COVAX is specifically designed to maximize the chances of success by investing in the development and manufacture of a large number of vaccine candidates at the same time.
With the world’s largest and most diverse vaccine portfolio – which currently comprises nine candidates already in development and a further nine or more under evaluation – COVAX will act as a global insurance policy.
Under this framework, member countries that have bilateral deals will still have vaccine access options in the event that those gambles fail, and the majority of countries that have no other options will be extended a critical lifeline.
COVAX’s initial aim is to have two billion vaccine doses available by the end of 2021, as that should be enough to protect high-risk/vulnerable populations and frontline health-care workers.
The delivery of COVID-19 vaccines will be the single largest vaccine deployment the world has ever seen, and it will have to be executed at a time when misinformation (the “infodemic”) is threatening to undermine public confidence in vaccine safety.
Second, public-health authorities need to enlist migrant communities in the process of contact tracing, which will be key to controlling the virus until an effective vaccine emerges.
A fourth priority is to ensure that migrants have fair access to a COVID-19 vaccine once one becomes available.
For starters, leading pharmaceutical companies have redirected resources toward the development of COVID-19 diagnostics, therapeutics, and, one hopes, a vaccine.
An apparent example of this came to light in October 2017, when the vaccine maker Sanofi paid $61.5 million to settle a case that was pending in a federal district court in New Jersey.
The suit alleged that when another company planned to compete against Sanofi’s pediatric meningitis vaccine Menactra, Sanofi hiked Menactra’s price by up to 34.5% unless buyers agreed to purchase all of its vaccines exclusively.
In a grim recent assessment of the global costs of the COVID-19 crisis, the Bill & Melinda Gates Foundation reported that in 25 weeks, the pandemic had set the world back about 25 years in terms of vaccine coverage – a good proxy for how health systems are functioning overall.
And, with no known vaccine or effective cure, the world has few weapons with which to fight it.
According to the Imperial College, even if the peak is reached soon, reverse waves of smaller outbreaks could require repeated lockdowns, until an effective vaccine is developed, tested, manufactured, and distributed widely – a process that will take a minimum of 12-18 months.
It has used the world’s most decisive measures to suppress a fulminant pandemic (after the first outbreak in Wuhan) and may well be on the way to producing the first useful vaccine.
Successful Immigration and the New German VaccineMUNICH – The world took note when the German start-up BioNTech announced its breakthrough in the development of a new type of vaccine to combat COVID-19.
After testing tens of thousands of people, BioNTech’s vaccine has been shown to be 95% effective in providing protection for those who would otherwise have been infected.
The company was the first to apply for emergency use authorization for a coronavirus vaccine in the United States, and it has announced that it will soon take similar steps in Europe.
The great advantage of this approach is that it allows for the production of more than one billion vaccine doses within the space of just a few months.
Indeed, delivery contracts for millions of doses of the vaccine are already in place.
For some childhood diseases, the development of a vaccine was by itself decisive.
Back